CA-88 is a botanically derived auxiliary treatment that has been shown to exhibit healthful benefits for patients undergoing cancer chemotherapy and radiotherapy.

CA-88 is a botanically derived compound that has been shown in preliminary studies to help relieve leukopenia, nausea, parageusia, quadriplegia, anesthesia and hearing loss, side effects that are associated with cancer chemotherapy and radiotherapy. CA-88 was developed based on the results of in vitro assays, in vivo animal models and preliminary human studies. The product is a food product, nontoxic, orally taken, convenient to carry, does not require in-patient treatment, and has potential to be developed into medicine. In animal and preliminary human studies, CA-88 showed potential for elevating immune function to inhibit growth of cancer cells. Preventative cancer functionality was also exhibited on studies in a conventional BALB/c mouse, while preliminary toxicity studies showed no deleterious effects of the compound on the test subjects. In vitro tests, in vivo animal tests and preliminary human clinical trial data are available on request.

Preclinical

USA, EU, Canada, Australia and Taiwan patents filed.

Drug development - pre-clinical. In vitro tests, in vivo animal tests and preliminary human studies are available on request.

Healthy food development - food product launched in 2005. In vitro tests, in vivo animal tests and human clinical trial data are available on request.

Biotechnology companies that are interested in developing CA-88 into a drug following FDA guidelines.

Companies or research institutes that are seeking collaboration for commercial or scientific purposes.